# Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma

> **NCT02883153** · PHASE2,PHASE3 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Zirconium-89 girentuximab PET/CT

## Key facts

- **NCT ID:** NCT02883153
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-06-06
- **Final completion:** 2017-06-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02883153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02883153, "Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02883153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*